Atea Pharmaceuticals (AVIR) EBIT Margin (2021)
Historic EBIT Margin for Atea Pharmaceuticals (AVIR) over the last 1 years, with Q4 2021 value amounting to 63.06%.
- Atea Pharmaceuticals' EBIT Margin changed N/A to 63.06% in Q4 2021 from the same period last year, while for Sep 2022 it was 15.83%, marking a year-over-year decrease of 79400.0%. This contributed to the annual value of 39.38% for FY2021, which is 620600.0% up from last year.
- As of Q4 2021, Atea Pharmaceuticals' EBIT Margin stood at 63.06%.
- In the past 5 years, Atea Pharmaceuticals' EBIT Margin registered a high of 63.06% during Q4 2021, and its lowest value of 67.5% during Q3 2021.